HER2/Neu Negative Clinical Trial
— ITOMICOfficial title:
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Verified date | September 2021 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This pilot research trial studies collecting, analyzing, and storing samples from patients with triple negative breast cancer (breast cancer cells that do not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 protein) that has spread to other places in the body receiving anti-cancer therapy. Studying samples of tissue, blood, buccal swab, saliva, and urine in the laboratory from patients receiving anti-cancer therapy may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
Status | Terminated |
Enrollment | 31 |
Est. completion date | June 30, 2018 |
Est. primary completion date | June 30, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects have metastatic TNBC - Disease suitable for analysis from either (a) or (b) below: - (a) Research biopsy - Tumor tissue, which can include bone disease, as determined by physical exam or imaging (as assessed by a trained specialist in radiology) - Must be collected before the subject receives treatment with a drug they have not received previously - (b) Standard of care biopsy - Tumor tissue available from a previous biopsy as standard of care (to be determined by the principal investigator [PI] or his designee) - Must have been collected before subject receives treatment with a drug they have not received previously - May begin treatment either after enrollment or within several weeks prior to enrollment - Subjects must be medically fit and willing to undergo repeated tissue biopsies or surgical procedures to get tumor tissue - Procedure-specific signed informed consent prior to initiation of any study-related procedures - Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (or a Karnofsky performance status of >= 50%) - Agree to allow their de-identified clinical and laboratory data to be posted to publicly available databases such as database of Genotypes and Phenotypes (dbGaP) Exclusion Criteria: - Bevacizumab treatment within 4 weeks prior to biopsy - Anticoagulation therapy, unless reversed at the time of biopsy - The enrolling study oncologist has decided that the subject is not fit enough to undergo repeated tissue biopsies - Presence of a condition or abnormality that in the opinion of the enrolling investigator would compromise the safety of the subject or the quality of the data - Significant bleeding disorder - Known brain metastases that have not or will not be treated - Subjects with a life expectancy of less than 6 months - Prisoners - Inability to give informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
United States | Northwest Medical Specialties PLLC | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of adverse events resulting from performing multiple biopsies measured by the presence of biopsy-related complications, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 | The frequency of adverse events associated with multiple repeated study-related biopsies (or leukapheresis runs) will be determined using simple statistics. | Within 1 week of biopsy | |
Primary | Infrastructure for acquiring, storing, retrieving and analyzing panomic data from clinical tumor specimens in a clinically relevant timeframe from participating sites | Findings of potential clinical significance will be included in the reports provided to subjects and oncologists. Similarly, as new information becomes available, information of significance to understanding a subject's tumor or germline genomes may become apparent. | Up to 2 years | |
Secondary | Change in subject perceptions regarding panomic data and its application to cancer treatment assessed by Intensive Trial of OMics in Cancer baseline and follow up questionnaires | Subject perceptions regarding the value of panomic testing in predicting the optimal treatment for subjects with cancer and for predicting the risk for developing other inherited diseases will be collected. | Baseline to 2 years | |
Secondary | Develop process improvements | The yield of successfully performing various types of analyses from clinically indicated- and study-related biopsies and leukapheresis specimens as well as the time frame necessary for returning reports will be monitored. | Up to 2 years | |
Secondary | Development and improvement of infrastructure for storing and working with data from subject biopsies | Data from subjects will be used to test the infrastructure being developing and identify areas that need to be improved. | Up to 2 years | |
Secondary | Methods required to analyze and integrate data across subjects and with data from the public domain | Methods and software that can facilitate comparing data from subjects with that deposited in the public domain will be developed. | Up to 2 years | |
Secondary | Molecular changes associated with treatment response or resistance | A number of statistical approaches will be used. Will be evaluated by comparing biopsies taken from the same subject pre- and post- anti-cancer treatment, and relating these changes to each subject's outcome. | Up to 2 years | |
Secondary | Number or frequencies of biopsies or leukapheresis runs | Safety and feasibility data will be analyzed and the frequency, nature, and severity of adverse events will be summarized. | Up to 2 years | |
Secondary | Removal of any unnecessary biopsies or generation of redundant data | Data across biopsies taken from the same individual at the same time point will be compared to assess the need for multiple biopsies. | Up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT01928186 -
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
|
N/A | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Terminated |
NCT02892734 -
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03723928 -
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
|
N/A | |
Completed |
NCT00390455 -
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
|
Phase 3 | |
Recruiting |
NCT03213041 -
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT03238703 -
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
|
Phase 4 | |
Active, not recruiting |
NCT02876107 -
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT01149356 -
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02445391 -
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
|
Phase 3 | |
Completed |
NCT01964924 -
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT03070002 -
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
|
Phase 2 | |
Completed |
NCT00785291 -
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
|
Phase 3 | |
Completed |
NCT02120469 -
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02744053 -
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
|
Early Phase 1 | |
Terminated |
NCT01071564 -
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Active, not recruiting |
NCT03359954 -
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT01251874 -
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT03291938 -
IACS-010759 in Advanced Cancers
|
Phase 1 |